Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;12(11):1647-1655.
doi: 10.1111/1759-7714.13982. Epub 2021 May 7.

Liquid biopsies to distinguish malignant from benign pulmonary nodules

Rui Tao  1 , Wei Cao  2 , Feng Zhu  3 , Jinfu Nie  4   5 , Hongzhi Wang  4   5 , Lixiang Wang  2 , Pengcheng Liu  1 , Hailong Chen  1 , Bo Hong  4   5 , Dahai Zhao  1
Affiliations
Review

Liquid biopsies to distinguish malignant from benign pulmonary nodules

Rui Tao et al. Thorac Cancer. 2021 Jun.

Abstract

Over the past decades, low-dose computed tomography (LD-CT) screening has been widely used for the early detection of lung cancer. Increasing numbers of indeterminate pulmonary nodules are now being discovered. However, it remains challenging to distinguish malignant from benign pulmonary nodules, especially those considered to be small or ground-glass (GGN) nodules. Liquid biopsies have been successfully applied in the diagnosis of advanced lung cancer, and the potential value for early detection of lung cancer has made great progress. Recent studies have demonstrated the value of various blood-based tumor biomarkers in determining the nature of pulmonary nodules, including cell-free DNA (cfDNA), microRNAs (miRNAs), circulating tumor cells (CTCs) and tumor-associated autoantibodies (AAbs). In this review, we summarize the latest progress of liquid biopsies, and their potential applications and challenges in the diagnosis of malignant pulmonary nodules.

Keywords: biomarker; cell-free DNA; liquid biopsy; miRNA; pulmonary nodule diagnosis.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no conflict of interest exists.

Figures

FIGURE 1
FIGURE 1
Schematic representation of liquid biopsies to aid the diagnosis of pulmonary nodules detected by low dose computed tomography (LD‐CT). These biomarkers for liquid biopsies include cell‐free DNA (cfDNA), microRNAs (miRNAs), circulating tumor cells (CTC) and autoantibodies (AAbs)
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. - PubMed
    1. Tang Y, Qiao G, Xu E, Xuan Y, Liao M, Yin G. Biomarkers for early diagnosis, prognosis, prediction, and recurrence monitoring of non‐small cell lung cancer. Onco Targets Ther. 2017;10:4527–34. - PMC - PubMed
    1. MacMahon H, Naidich DP, Goo JM, Lee KS, Leung ANC, Mayo JR, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology. 2017;284(1):228–43. - PubMed
    1. Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, et al. NCCN guidelines insights: non‐small cell lung cancer, version 5.2018. J Natl Compr Canc Netw. 2018;16(7):807–21. - PubMed
    1. Khan T, Usman Y, Abdo T, Chaudry F, Keddissi JI, Youness HA. Diagnosis and management of peripheral lung nodule. Ann Transl Med. 2019;7(15):348. - PMC - PubMed

Publication types

LinkOut - more resources